Contract research, development and manufacturing organisation (CRDMO) Pace Life Sciences has expanded its aseptic fill-finish processing site in Salem, New Hampshire.
The facility now houses an isolated vial filling ling designed to facilitate smaller batch size manufacturing with high sterility assurance and EU Annex 1 compliance — meaning the company can better serve its clinical-stage clients.
Through the remodelling and expansion of the New Hampshire site, Pace has also bolstered its cGMP manufacturing capacity; particularly in the injectable space.
The company will now be able to serve clients looking to develop or manufacture a range of therapeutic modalities, including vaccines, gene therapies, antibodies and protein-based therapeutics.
Pace's new Centre of Excellence will officially open on July 16, 2025, where guided facility tours will be available to attendees.
“We're always looking to improve at Pace Life Sciences, and our team recognised an opportunity to enhance and expand our capabilities," noted the company's President, Dawn Von Rohr.
"This was in direct response to out past success in partnering with clients on small molecule fill-finish programmes, as well as the increasing demand for fill-finish manufacturing generated by the growth of biologics and other next-generation therapeutic modalities," she added.
"The remodel of our state-of-the-art facility in Salem, NH, ensures that we can scale alongside our clients as their programmes evolve and regulatory expectations advance. We look forward to welcoming visitors to showcase our advanced capabilities and enhancements.”
